Cure8 news brief
Phase 2a data suggest a combo approach may improve endoscopic remission versus Skyrizi alone, which could matter for future Crohn's treatment options and for patients who have failed prior advanced therapies.
Because this is early-stage data and the study is open-label and ongoing, it’s an early signal rather than definitive proof.
Patients with Crohn’s disease, particularly those who have failed prior biologics; clinicians who treat IBD; researchers and investors tracking drug development and combination strategies.
The trial described is Phase 2a and open-label, with Week 24 endoscopic remission cited as a key result. The study enrolled patients many of whom had prior advanced-therapy failure; safety signals reported in the article show similar serious adverse event rates between arms.
The company plans a Phase 2b testing a higher dose of the α4β7-targeting drug and expects eventual co-formulation into a single injection.
The article primarily interprets clinical data for investors rather than providing exhaustive clinical details; it does not report statistical testing (p-values) in the supplied text, and the combination remains years from potential approval.
The report is a finance/press summary of conference results, not a peer-reviewed paper; the trial is open-label, ongoing, and the article does not present p-values. The combination and regulatory approval, if successful, are several years away. The article compares different trials with different designs, which limits direct comparisons of remission rates.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
